康泰医学
(300869)
| 流通市值：42.56亿 | | | 总市值：67.50亿 |
| 流通股本：2.53亿 | | | 总股本：4.02亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 343,992,692.71 | 217,549,459.94 | 111,844,411.72 | 479,805,174.09 |
| 营业收入 | 343,992,692.71 | 217,549,459.94 | 111,844,411.72 | 479,805,174.09 |
| 二、营业总成本 | 335,255,538.73 | 192,423,187.84 | 93,516,783.56 | 467,672,298.13 |
| 营业成本 | 155,727,261.42 | 86,114,414.21 | 46,809,494 | 243,022,612.99 |
| 税金及附加 | 6,261,146.53 | 4,931,403.2 | 3,472,842.69 | 8,463,226.61 |
| 销售费用 | 79,276,561.67 | 42,412,618.74 | 15,862,954.35 | 88,527,030.1 |
| 管理费用 | 27,165,697.13 | 17,112,193.37 | 8,074,873.75 | 40,822,155.41 |
| 研发费用 | 69,070,735.32 | 46,481,133.59 | 22,572,126.74 | 105,156,379.17 |
| 财务费用 | -2,245,863.34 | -4,628,575.27 | -3,275,507.97 | -18,319,106.15 |
| 其中:利息费用 | - | - | - | 35,299,989.3 |
| 其中:利息收入 | - | - | - | 48,539,438.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,329,630.79 | 2,752,724.31 | 2,307,189.11 | 1,588,083.19 |
| 加:投资收益 | 6,633,235.12 | 849,480.1 | 664,115.06 | 22,518,834.81 |
| 资产处置收益 | 5,857.18 | 0 | -16,317.68 | 166,241.78 |
| 资产减值损失(新) | -18,155,116.54 | -16,022,591.5 | -6,870,205.28 | -109,445,716.65 |
| 信用减值损失(新) | -117,804.32 | 107,054.65 | -4,771.71 | -1,820,714.08 |
| 其他收益 | 9,644,780.94 | 5,523,541.59 | 2,817,310.37 | 7,310,075.54 |
| 四、营业利润 | 10,077,737.15 | 18,336,481.25 | 17,224,948.03 | -67,550,319.45 |
| 加:营业外收入 | 688,444.12 | 495,178.41 | 189,886.3 | 1,627,737.34 |
| 减:营业外支出 | 655,257.13 | 338,919 | 268,394.62 | 7,964,744.43 |
| 五、利润总额 | 10,110,924.14 | 18,492,740.66 | 17,146,439.71 | -73,887,326.54 |
| 减:所得税费用 | 711,081.74 | 1,555,167.49 | 710,671.93 | 4,015,238.14 |
| 六、净利润 | 9,399,842.4 | 16,937,573.17 | 16,435,767.78 | -77,902,564.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,399,842.4 | 16,937,573.17 | 16,435,767.78 | -77,902,564.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,399,842.4 | 16,937,573.17 | 16,435,767.78 | -77,902,564.68 |
| 扣除非经常损益后的净利润 | -3,397,211.81 | 12,453,493.18 | 13,769,664.12 | -95,079,251.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.04 | 0.04 | -0.19 |
| (二)稀释每股收益 | 0.02 | 0.04 | - | -0.17 |
| 八、其他综合收益 | -245,172.4 | 125,719.53 | 138,597.25 | 396,628.48 |
| 归属于母公司股东的其他综合收益 | -245,172.4 | 125,719.53 | 138,597.25 | 396,628.48 |
| 九、综合收益总额 | 9,154,670 | 17,063,292.7 | 16,574,365.03 | -77,505,936.2 |
| 归属于母公司股东的综合收益总额 | 9,154,670 | 17,063,292.7 | 16,574,365.03 | -77,505,936.2 |
| 公告日期 | 2025-10-30 | 2025-08-29 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |